113490-74-7

Basic information

• Product Name: 1,2-Pyrrolidinedicarboxylic acid, 4-azido-, 2-methyl 1-(phenylmethyl) ester, (2S,4S)-
• CAS NO: 113490-74-7
• Molecular Formula: C14H16N4O4
• Molecular Weight: 304.305
• Mol File: 113490-74-7.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1,2-Pyrrolidinedicarboxylic acid, 4-azido-, 2-methyl 1-(phenylmethyl) ester, (2S,4S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-Pyrrolidinedicarboxylic acid, 4-azido-, 2-methyl 1-(phenylmethyl) ester, (2S,4S)-(113490-74-7)
• EPA Substance Registry System: 1,2-Pyrrolidinedicarboxylic acid, 4-azido-, 2-methyl 1-(phenylmethyl) ester, (2S,4S)-(113490-74-7)

Safety Data

• Hazardous Substances Data: 113490-74-7(Hazardous Substances Data)

Upstream product

• 1499-56-5 (R)-4-hydroxy-L-proline ethyl ester 
• 13504-85-3 (2S,4R)-1-(benzyloxycarbonyl)-4-hydroxypyrrolidine-2-carboxylic acid 
• 501-53-1 benzyl chloroformate 
• 64187-48-0 methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate 
• 117811-78-6 methyl (2S,4R)-1-benzyloxycarbonyl-4-methanesulfonyloxypyrrolidine-2-carboxylate 

Downstream Products

• 168263-80-7 methyl (2S,4S)-1-benzyloxycarbonyl-4-tert-butoxycarbonylaminopyrrolidine-2-carboxylate 
• 1321614-26-9 1-benzyl 2-methyl (2S,4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}pyrrolidine-1,2-dicarboxylate 
• 1321614-25-8 methyl (4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate 
• 1321614-31-6 methyl (4S)-1-[(2S)-3-(acetylsulfanyl)-2-methylpropanoyl]-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate 
• 1321614-34-9 (4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline 
• 1321614-42-9 methyl N-[(1S)-1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl-(4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-prolinate 
• 1321614-45-2 N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl-(4S)-4-{[(3R)-3-[(tert-butoxycarbonyl)amino]-4-(2,4,5-trifluorophenyl)butanoyl]amino}-L-proline 
• 1279200-14-4 C₁₃H₁₈N₂O₃ 
• 380648-98-6 carbonic acid 1-[(4-benzyloxycarbonylamino-2-oxo-2H-pyrimidin-1-yl)-acetyl]-4-tert-butoxycarbonylamino-pyrrolidin-2-ylmethyl ester 4-nitro-phenyl ester 
• 380648-97-5 {(2S,4S)-4-t-butoxycarbonylamino-1-[(thymin-1-yl)methylcarbonyl]-pyrrolidin-2-yl}methyl 4-nitrophenyl carbonate 
• 380648-96-4 {1-[2-((2S,4S)-4-tert-Butoxycarbonylamino-2-hydroxymethyl-pyrrolidin-1-yl)-2-oxo-ethyl]-2-oxo-1,2-dihydro-pyrimidin-4-yl}-carbamic acid benzyl ester 
• 380648-94-2 benzyl (2S,4S)-4-((tert-butoxycarbonyl)amino)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 663948-85-4 tert-butyl ((3S,5S)-5-(hydroxymethyl)pyrrolidin-3-yl)carbamate 
• 168263-82-9 (2S,4S)-methyl 4-(tert-butoxycarbonylamino)pyrrolidine-2-carboxylate 

Relevant articles and documents

DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE

Provided herein are a dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B. Specifically, provided herein is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification. Also provided herein is use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.

PROLINE DERIVATIVES FOR USE IN THE TREATMENT OF DIABETES

The present invention provides novel heterocyclic compounds and methods of preparing such compounds. The compounds of the invention are useful for palliative, curative or prophylactic treatment of diseases or conditions of diabetes and/or hypertension. This invention also relates to pharmaceutical compositions containing the compounds of the present invention, and methods for palliative, curative or prophylactic treatment of diseases or conditions of diabetes and/or hypertension. The present invention also provides pharmaceutical compositions consisting of the heterocyclic compounds along with one or more dyslipidemic agents, antiobesity agents, anti-hyperglycemic agents, antihypertensive agents and anti-inflammatory agents.

Two prolines with a difference: contrasting stereoelectronic effects of 4R/S-aminoproline on triplex stability in collagen peptides [pro(X)-pro(Y)-Gly]n.

4R/S-Aminoprolines when present in the X-position of collagen peptide [pro(X)-pro(Y)-Gly]n exhibit pH- and stereochemistry-dependent effects on triplex stability.